Wall Street expects a year-over-year decline in earnings on lower revenues when Kyntra Bio (KYNB) reports results for the quarter ended December 2025. While this widely-known consensus outlook is ...

This clinical-stage biotech advances oncology therapies with a pipeline of novel small molecule inhibitors for hard-to-treat ...

ImmunityBio's stock has roughly quintupled so far in 2026 as the company continues to deliver good news for investors.

That morning, Belite announced that its leading drug candidate, tinlarebant, met its primary endpoint in a phase 3 trial. The medicine was being tested to determine its efficacy in treating ...

Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...

Nuvation Bio upgraded to Hold as IBTROZI adoption improves, but competition and pipeline risks loom. Click here to read my latest analysis of NUVB stock.

Shares of Nuvation Bio (NYSE: NUVB) were skyrocketing 15.7% higher as of 11:20 a.m. ET on Tuesday. The big jump came after two positive developments for the cancer-focused drugmaker. Which news ...

Vor Bio granted Dr. Qing Zuraw stock options and RSUs as part of her employment package, effective July 17, 2025. Vor Bio, a biotechnology company focused on treating autoimmune diseases, announced ...

Investing.com -- Gossamer Bio (NASDAQ:GOSS) shares fell 80% Monday after the company’s seralutinib failed to meet the primary endpoint in its Phase 3 PROSERA trial for pulmonary arterial hypertension.

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (PASG) (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of ...